Yu-Hong Suo

Yu-Hong Suo

Auto-generated profile, based on publicly available information

Yu-Hong Suo

Department of Hepatobiliary Oncology, Liver Cancer Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2024 in Acta Pharmacologica Sinica
Verified
Journal Article
Closed access
PDF file
CHChun-Yu Hou
Chun-Yu Hou
YSYu-Hong Suo
Yu-Hong Suo
PLPan Lv
Pan Lv
HYHong-Feng Yuan
Hong-Feng Yuan
LZLina Zhao
Lina Zhao
XZXiao-Dong Zhang
Xiao-Dong Zhang

3 July 2023 in Biomolecules and Biomedicine
Verified
Journal Article
Open access
PDF file
YSYuhong Suo
Yuhong Suo
CHChunyu Hou
Chunyu Hou
Guang YangGuang Yang
Guang Yang
HYHongfeng Yuan
Hongfeng Yuan
LZLina Zhao
Lina Zhao
WLWei Lu
Wei Lu
The Fc fragment of IgG binding protein (FCGBP) has been confirmed to play an important role in various cancers. However, the specific role of FCGBP in hepatocellular carcinoma (HCC) remains undefined. Thus, in this study, the enrichment analyses (Gene Ontology, Kyoto Encyclopedia of Genes and Genomes, and Gene Set Enrichment Analysis) of FCGBP in HCC and extensive bioinformatic analyses using data of clinicopathologic characteristics, genetic expression and alterations, and immune cell infiltration were perfomed. Quantitative real-time polymerase chain reaction (qRT-PCR) was used to verify the expression of FCGBP in both HCC tissues and cell lines. The subsequent results confirmed thatFCGBP overexpression positively correlated with poor prognosis in patients with HCC. Additionally, FCGBP expression could effectively distinguish tumor tissues from normal tissues, which was verified by qRT-PCR. The result was further confirmed by using HCC cell lines. The time-dependent survival receiver operator characteristic curve exhibited the strong ability of FCGBP to predict survival in patients with HCC. Additionally, we revealed the strong relationship between FCGBP expression and a number of classic regulatory targets and classical oncogenic signaling pathways of tumors. Finally, FCGBP was involved in the regulation of immune infiltration in HCC. Therefore, FCGBP has potential value in the diagnosis, treatment, and prognosis of HCC and may be a potential biomarker or therapeutic target.